Modality
siRNA
MOA
SGLT2i
Target
GIP-R
Pathway
Epigenetic
MGACC
Development Pipeline
Preclinical
Aug 2017
→ Jul 2031
PreclinicalCurrent
NCT03638902
1,313 pts·ACC
2017-10→2031-07·Active
NCT07071056
1,782 pts·ACC
2017-08→2025-07·Terminated
3,095 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-258mo agoInterim· ACC
2031-07-115.3y awayInterim· ACC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Termina…
Preclinical
Active
Catalysts
Interim
2025-07-25 · 8mo ago
ACC
Interim
2031-07-11 · 5.3y away
ACC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03638902 | Preclinical | ACC | Active | 1313 | HAM-D |
| NCT07071056 | Preclinical | ACC | Terminated | 1782 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |